Strong antibody and cell-mediated immune responses induced by low antigen doses, long-duration immune responses, plus low risk for allergic reactions or other adverse events are all hallmarks of Isconovas adjuvant technology.
These well-recognised qualities confer Matrix™ adjuvants a number of important advantages over other types of adjuvants. For example, companies developing other adjuvants based on novel, less well characterised substances have been hampered by safety concerns and/or limited efficacy.
The Matrix™ technology generally induces strong cellular activation of both Th1 and Th2 types, thereby generating all classes and subclasses of antibodies, as well as potent cellular responses, e.g. cytotoxic T lymphocytes. Isconova’s new-generation Matrix-M™ adjuvant provides a potent adjuvant effect and is well tolerated, a performance step-up achieved by a patented new formulation of the adjuvant.
Stable and simple to use
Matrix™ technology also displays strongly improved chemical stability of the Quillaja saponines. The AbISCO® adjuvant research reagent has a shelf-life of several years in aqueous solutions at +2-8°C, for example. In addition, the matrix particles are simply mixed with the vaccine antigen post-manufacturing, giving great flexibility in vaccine design as well as significant production advantages.
Isconova adjuvant technology is based on matrix complexes formed by a specific mixture of Quillaja saponin, cholesterol and phospholipid.
Stronger and longer-lasting immunological response allows highly effective vaccine development.
Isconovas adjuvant technology is highly efficient; the exceptionally strong, long-lasting and balanced immune response that is induced allows new vaccines addressing unmet medical needs to be developed.
Antigen-saving reduces production costs
The strong immune response and opportunity to reduce the antigen dose needed can significantly reduce the production cost of vaccine manufacture.
Isconova’s Matrix-M™ can be of immense value when faced with inadequate vaccine manufacturing capacity and an emerging threat such as an influenza pandemic.